Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

Investors Business Daily

Guillain-Barre Syndrome 'More Common Than Expected' In RSV Vaccinated Older Adults: CDC

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

Medical Daily

Top 4 Pharma Stocks for Long-Term Value Investors in 2024

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

FTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale

GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results.

Evening Standard

‘The issue is when to pull the trigger’: how prepared are we for human bird flu?

The H5N1 virus has been devastating bird populations, and is now infecting mammals too. Is human-to-human transmission next? And are we ready for another pandemic?

The Guardian - UK

Moderna Tumbles After The FDA Throws A Curveball On Its Second Product

Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

Investors Business Daily

GSK Stock Today: Buying An August Covered Call Boosts Your Return By This Much

This covered call equates to a 6.26% return, or 22.17% on an annualized basis.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Could better asthma inhalers help patients, and the planet too?

Some doctors are promoting propellant-free inhalers over puff inhalers that emit greenhouse gases. Climate change can exacerbate respiratory ills because of more fires, air pollution and allergens.

WEKU

Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views

Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.

Investors Business Daily

3 Popular Pharma Stocks Worth Buying Now

The pharmaceutical industry is set for solid growth due to increased demand for effective treatments for regular and rare diseases, an aging population, and ongoing innovations in pharma technology. Hence, investors could consider buying quality pharmaceutical stocks such as Collegium Pharmaceutical (COLL), Novo Nordisk (NVO), and GSK (GSK). Read on.

StockNews.com

FTSE 100 Live 1 May: US Fed notes ‘lack of further progress’ on inflation as it holds interest rates

Forecast-beating results by Shell and Standard Chartered today boosted their shares during another robust session for the FTSE 100 index.

Evening Standard

Asthma Medication Shortage Puts Children At Risk

Families face challenges in affording essential asthma medication for children due to high costs and limited insurance coverage, highlighting the need for ...

Top News

GSK Settles California Lawsuit On Zantac Heartburn Drug

GSK reaches settlement in California lawsuit related to Zantac amidst ongoing legal challenges over cancer risks.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks to Anchor Your Portfolio

The pharma market is poised to thrive due to the continuous medicinal advancements to meet the escalating demand for chronic disease treatment, technological advancements, and increased research and development. Given this backdrop, quality pharma stocks Procaps Group S.A. (PROC), Supernus Pharmaceuticals (SUPN), and GSK plc (GSK) could be wise portfolio…

International Business Times

30 Most Powerful Women In Business: The Titans Of Industry

Here are the women, who are forging paths and breaking barriers across industries, showcasing exceptional leadership and innovation.

Investors Business Daily

Moderna Surges 14% After Covid Vaccine-Maker Surprises With Fourth-Quarter Profit

Moderna stock surged Thursday after the firm beat quarterly expectations, including turning around a surprise profit.

Evening Standard

GSK’s Julie Brown to join drinks giant Diageo’s board

Guinness and Smirnoff vodka maker Diageo has appointed Julie Brown as a non-executive director with effect from August 5.

Barchart

1 Pharma Stock to Buy Near 52-Week Highs

GSK's stock has been a poor performer for years. But recently, the pharma stock keeps setting new 52-week highs, thanks to its blockbuster vaccines.

StockNews.com

Unleash Gain Potential With 3 Pharma Stocks to Consider

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

Evening Standard

Arm becomes Britain's sixth most valuable company after shares rise 50%

FTSE stalwarts BP, GSK and Diageo have been left in the dust by the UK’s biggest Nasdaq-listed firm

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.